Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

February 28, 2014

Conditions
Chronic Hepatitis B
Interventions
DRUG

Entecavir

Tablets, Oral, 1 mg, once daily, 96 weeks

DRUG

Tenofovir

Tablets, Oral, 300 mg, once daily, 96 weeks

Trial Locations (28)

10969

Local Institution, Berlin

13353

Local Institution, Berlin

20099

Local Institution, Hamburg

20122

Local Institution, Milan

20246

Local Institution, Hamburg

30625

Local Institution, Hanover

45067

Local Institution, Orléans

46014

Local Institution, Valencia

50012

Local Institution, Bagno A Ripoli (Fi)

67000

Local Institution, Strasbourg

69120

Local Institution, Heindelberg

69317

Local Institution, Lyon

70124

Local Institution, Bari

71100

Local Institution, Foggia

72076

Local Institution, Tübingen

81675

Local Institution, München

92110

Local Institution, Clichy

1105 AZ

Local Institution, Amsterdam

6815 AD

Local Institution, Arnhem

3015 CE

Local Institution, Rotterdam

25-317

Local Institution, Kielce

31-531

Local Institution, Krakow

91-347

Local Institution, Lodz

50-349

Local Institution, Wroclaw

021105

Local Institution, Bucharest

022328

Local Institution, Burcuresti

300 002

Local Institution, Timișoara

08025

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY